DA-1229

DRUG5 trials

Sponsors

Dong-A Pharmaceutical Co., Ltd., Dong-A ST Co., Ltd.

Conditions

Calcific Aortic Valve DiseaseDiabetes Mellitis Type 2HealthyRenal ImpairmentType 2 Diabetes Mellitus

Phase 1

A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects

Dong-A Pharmaceutical Co., Ltd.Diabetes Mellitis Type 2

Start: 2009-05-31End: 2010-03-31Target: 110Updated: 2009-08-24

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects

CompletedNCT01941199

Dong-A Pharmaceutical Co., Ltd.Type 2 Diabetes Mellitus

Start: 2013-07-31Updated: 2013-11-27

PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients

CompletedNCT02214693

Dong-A ST Co., Ltd.Renal Impairment

Start: 2014-07-31Updated: 2015-08-27

Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229

Dong-A ST Co., Ltd.Healthy

Start: 2014-09-30End: 2015-01-31Target: 12Updated: 2014-10-20

Phase 2

Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD

CompletedNCT04055883

Dong-A ST Co., Ltd.Calcific Aortic Valve Disease

Start: 2019-08-26End: 2023-02-01Updated: 2023-03-03

Related Papers

Effect of Evogliptin on the Progression of Aortic Valvular Calcification.

2024-09-019 citations

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.

2012-09-0121 citations